The many aspects of endothelins in ischemia-reperfusion injury: Emergence of a key mediator

Journal of Investigative Surgery

Volumn 11, Issue 5, 1998, Pages 297-313

  Battistini, Bruno ^a   Dussault, Patrick ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Antagonists; Conversion; Endothelins; Inflammation; Inhibitors; Injury; Ischemia reperfusion; Receptors; Transplantation

Indexed keywords

CYCLOSPORIN; ENDOTHELIN; ENDOTHELIN B RECEPTOR ANTAGONIST; IMMUNOSUPPRESSIVE AGENT; MITOGENIC AGENT; PEPTIDE; TACROLIMUS; VASOCONSTRICTOR AGENT;

BRAIN ISCHEMIA; CARDIOVASCULAR SYSTEM; GRAFT REJECTION; HEART DISEASE; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEMORRHAGIC SHOCK; HUMAN; HYPERTENSION; ISCHEMIA; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; KIDNEY GRAFT; KIDNEY ISCHEMIA; LIVER ISCHEMIA; LIVER TRANSPLANTATION; LUNG DISEASE; MYOPATHY; NONHUMAN; ORGAN TRANSPLANTATION; PATHOPHYSIOLOGY; PREECLAMPSIA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REPERFUSION INJURY; REVIEW; SUBARACHNOID HEMORRHAGE;

EID: 0031736083     PISSN: 08941939     EISSN: None     Source Type: Journal    
DOI: 10.3109/08941939809032207     Document Type: Review

References (151)

1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent constrictor peptide produced by vascular endothelial cells. Nature. 1988;332,411-415.
2. Rubanyi GM, Polokoff MA. Endothelins: Molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev. 1994;46:325-415.
3. Battistini B, D'Orléans-Juste P, Sirois P. Endothelins in physiopathology; Circulating plasma levels and presence in other biological fluids. Lab Invest. 1993;68:600-628.
4. Battistini B, Botting R, Warner TD. Endothelins: A knockout in London. Trends Pharmacol Sci. 1995;16:217-222.
5. Warner TD, Elliott JD, Ohlstein EH. California dreamin' bout endothelin: Emerging new therapeutics. Trends Pharmacol Sci. 1996;17:177-181.
6. Douglas SA. Clinical development of endothelin receptor antagonists. Trends Pharmacol Sci. 1997;18:408-412.
7. Webb DJ, Monge JC, Rabelink TJ, Yanagisawa M. Endothelin: New discoveries and rapid progress in the clinic. Trends Pharmacol Sci. 1998;19:5-8.
8. Opgenorth TJ, Wu Wong JR, Shiosaki K. Endothelin-converting enzymes. FASEB J. 1992;6:2653-2659.
9. Turner AJ, Murphy U. Molecular pharmacology of endothelin converting enzymes. Biochem Pharmacol. 1996;51(2):91-102.
10. Schweizer A, Valdenaire O, Nelbock P, Deuschle U, Dumas JB, Edwards, Stumpf JG, Loffler BM. Human ECE-1: Three isoforms with disctinct subcellular localizations. Biochem J. 1997;328:871-877.
11. De Lombaert S, Stamford LB, Blanchard L, Tan J, Hoyer D, Diefenbacher CG, Wei D, Wallace EM, Moskal MA, Savage P, Jeng AY. Potent non-peptidic dual inhibitors of endothelin-converting enzyme and neutral endopeptidase 24.11. Biorg Med Chem. 1997;7:1059-1064.
12. Ahn K, Sisneros AM, Herman SB, Pan SM, Hupe D, Lee C, Nikam S, Cheng XM, Doherty AM, Schroeder RL, Haleen SJ, Kaw S, Emoto N, Yanagisawa M. Novel selective quinazoline inhibitors of endothelin converting enzyme-1. Biochem Biophys Res Commun. 1998;243(1):184-190.
13. Tonnessen T, Christensen G, Oie E, Holt E, Kjekshus H, Smiseth OA, Sejersted OM, Attramadal H. Increased cardiac expression of endothelin-1 mRNA in ischemic heart failure in rats. Cardiovasc Res. 1997;33(3):601-610.
14. Velasco CE, Jackson EK, Morrow JA, Vitola JV, Inagami T, Forman MB. Intravenous adenosine suppresses cardiac release of endothelin after myocardial ischaemia and reperfusion. Cardiovasc Res. 1993;27(1):121-128.
15. Tsuji S, Sawamura A, Watanabe H, Takihara K, Park SE, Azuma J. Plasma endothelin levels during myocardial ischemia and reperfusion. Life Sci. 1991;48(18):1745-1750.
16. Ray SG, Mcmurray JJ, Morton JJ, Dargie HJ. Circulating endothelin in acute ischaemic syndromes. Br Heart J. 1992;67(5):383-386.
17. Firth JD, Ratcliffe PJ. Organ distribution of the three rat endothelin messenger RNAs and the effects of ischemia on renal gene expression. J Clin Invest. 1992; 90(3):1023-1031.
18. Wu Weiping, Kuang Peigen, Li Zhenzhou. Changes of endothelin-1 gene expression in rat brains during ischemia and ischemic reperfusion. Chinese Med Sci J. 1996;11(4):228-231.
19. Duverger D, Viossat I, Chapelat M, Chabrier PE, Pirotzky E, Braquet P. Focal cerebral ischemia in the rat: Measurement of brain tissue endothelin. Circ Met Cerveau. 1992;9(2):85-93.
20. Viossat I, Duverger D, Chapelat M, Pirotzky E, Chabrier PE, Braquet P. Elevated tissue endothelin content during focal cerebral ischemia in the rat. J Cardiovasc Pharmacol. 1993;22(S8):S306-S309.
21. Willette RN, Ohlstein EH, Pullen M, Sauermelch CF, Cohen A, Nambi P. Transient forebrain ischemia alters acutely endothelin receptor density and immunoreactivity in gerbil brain. Life Sci. 1993;52(1):35-40.
22. Pluta RM, Boock RJ, Afshar JK, Clouse K, Bacic M, Ehrenreich H, Oldfield EH. Source and cause of endothelin-1 release into cerebrospinal fluid after subarachnoid hemorrhage. J Neurosurg. 1997;87(2):287-293.
23. Lampl Y, Fleminger G, Gilad R, Galron R, Sarova-Pinhas I, Sokolovsky M. Endothelin in cerebrospinal fluid and plasma of patients in the early stage of ischemic stroke. Stroke. 1997;28(10):1951-1955.
24. Spatz M, Stanimirovic D, Strasser A, McCarron RM. Nitro-L-arginine augments the endothelin-1 content of cerebrospinal fluid induced by cerebral ischemia. Brain Res. 1995;684(1):99-102.
25. Bian LG, Zhang TX, Zhao WG, Shen JK, Yang GY. Increased endothelin-1 in the rabbit model of middle cerebral artery occlusion. Neurosci Lett. 1994;174(1):47-50.
26. Takasu A, Yagi KI, Okada Y. Role of endothelin-1 in the failure of cerebral circulation after complete global cerebral ischemia. Resuscitation. 1995;30(1):69-73.
27. Ziv I, Fleminger G, Djaldetti R, Achiron A, Melamed E, Sokolovsky M. Increased plasma endothelin-1 in acute ischemic stroke. Stroke. 1992;23(7):1014-1016.
28. Nakamura S, Nishiyama R, Serizawa A, Yokoi Y, Suzuki S, Konno H, Baba S, Muro H. Hepatic release of endothelin-1 after warm ischemia: Reperfusion injury and its hemodynamic effect. Transplantation. 1995;59(5):679-684.
29. Gulluoglu BM, Aktan AO, Yegen C, Kurtel H, Yalin R. Endothelin release in augmented with captopril in rat ischemia-reperfusion injury of the liver. Res Exp Med. 1996;196(4):227-233.
30. Kawamura E, Yamanaka N, Okamoto E, Tomoda F, Furukawa K. Response of plasma and tissue endothelin-1 to liver ischemia and its implication in ischemia-reperfusion injury. Hepatology. 1995;21(4):1138-1143.
31. Urakami A, Todo S, Zhu Y, Zhang S, Jin MB, Ishizaki N, Shimamura T, Totsuka E, Subbotin V, Lee R, Starzl TE. Attenuation of ischemic liver injury by monoclonal anti-endothelin antibody, AwETN40. J Am Coll Surg. 1997;185(4):358-364.
32. Ota T, Hirai R, Urakami A, Soga H, Nawa S, Shimizu N. Endothelin-1 levels in portal venous blood in relation to hepatic tissue microcirculation disturbance and hepatic cell injury after isehemia/reperfusion. Surg Today. 1997;27(4):313-320.
33. Sakurai T, Yanagisawa M, Masaki T. Molecular characterization of endothelin receptors. Trends Pharmacol Sci. 1992;13:103-108.
34. Karne S, Jayawickreme CK, Lerner MR. Cloning and characterization of an endothelin-3 specific receptor (ETC receptor) from Xenopus laevis dermal melanophores. J Biol Chem. 1993;268:19126-19133.
35. Kumar C, Mwangi V, Nuthulaganti P, Wu HL, Pullen M, Brun K, Aiyar H, Morris RA, Naughton R, Nambi P. Cloning and characterization of a novel endothelin receptor from Xenopus heart. J Biol Chem. 1994;269: 13414-13420.
36. Warner TD, Battistini B, Doherty AM, Corder R. Endothelin receptor antagonists: Actions and rationale for their development. Biochem Pharmacol. 1994;48:625-635.
37. Liu J, Casley DJ, Nayler WG. Ischemia causes externalization of ET-1 binding sites in rat cardiac membranes. Biochem Biophys Res Commun. 1989;164:1220-1225.
38. 125I-labeled ET-1 binding in rat cardiac membranes. Am J Physiol. 1990;258:H829-H835.
39. 125I]ET-1 binding to rat cardiac membranes. J Cardiovasc Pharmacol. 1990;15:436-443.
40. Nayler WG, Ou RC, Gu XH, Casley DJ. Effect of amlodipine pretreatment on ischaemia-reperfusion-induced increases in cardiac endothelin-1 binding site density. J Cardiovasc Pharmacol. 1992;20(3):416-420.
41. Velasco C, Giaid A, Williamson J, Yanagisawa M. Myocardial ischemia and local ET-1 production. Eur Heart J. 1994;15(S):118.
42. Watts JA, Chapat S, Johnson DE, Janis RA. Effects of nisoldipine upon vasoconstrictor responses and binding of endothelin-1 in ischemic and reperfused rat hearts. J Cardiovasc Pharmacol. 1992;19(6):929-936.
43. Fu LX, Sun XY, Hedner T, Feng QP, Liang QM, Hoebeke J, Hjalmarson A. Decreased density of mesenteric arteries but not of myocardial endothelin receptors and function in rats with chronic ischemic heart failure. J Cardiovasc Pharmacol. 1993;22(2):177-182.
44. Stewart DJ, Baffour R. Ischemia-reperfusion potentiates ET-induced constriction in the coronary resistance bed. In: Endothelium-Derived Contracting Factors. Basel: Karger; 1990:212.
45. Neubauer S, Zimmermann S, Hirsch A, Pulzer F, Tian R, Bauer W, Bauer B, Ertl G. Effects of endothelin-1 in the isolated heart in ischemia/reperfusion and hypoxia/reoxygenation injury. J Mol Cell Cardiol. 1991; 23(12):1397-1409.
46. Saito T, Fushimi E, Abe T, Kimura Y, Takahashi K, Kudo Y, Nakagomi A, Miura M. Augmented contractile response to endothelin and blunted endothelium-dependent relaxation in post-ischemic reperfused coronary arteries. Jpn Cir J. 1992;56(7):657-670.
47. Kohzuki M, Onodera H, Yasujima M, Itoyama Y, Kanazawa M, Sato T, Abe K. Endothelin receptors in ischemic rat brain and Alzheimer brain. J Cardiovasc Pharmacol. 1995;26(S3):S329-S331.
48. Moreland S, McMullen DM, Delaney CL, Lee VG, Hunt JT. Venous smooth muscle contains vasoconstrictor ETB-like receptors. Biochem Biophys Res Commun. 1992;184: 100-106.
49. Seo B, Oemar BS, Siebenmann R, von Segesser L, Luscher TF. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels Circ. 1994;89:1203-1208.
50. Warner TD, Mitchell JA, de Nucci G, Vane JR. Endothelin-1 and endothelin-3 release EDRF from isolated perfused arterial vessels of the rat and rabbit. J Cardiovasc Pharmacol. 1989;13:S85-S88.
51. Bacon CR, Davenport AP. Endothelin receptors in human coronary artery and aorta. Br J Pharmacol. 1996; 117(5):986-992.
52. Balwierczak JL. Two subtypes of the ET receptor (ETA and ETB) mediate vasoconstriction in the perfused rat heart. J Cardiovasc Pharmacol. 1993;22(S8):S248-S551.
53. Teerlink JR, Breu V, Sprecher U, Clozel M, Clozel JP. Potent vasoconstriction mediated by ETB receptors in canine coronary arteries. Circ Res. 1994;74:105-114.
54. Battistini B, Forget MA, Laight D. Potential role for endothelins in systemic inflammatory response syndrome (SIRS) with particular relationship to cytokines. Shock. 1996;5(3):167-183.
55. Lopez Farrè A, Gomez Garre D, Bernabeu F, Lopez Novoa JM. A role for endothelin in the maintenance of post-ischaemic renal failure in the rat. J Physiol. 1991;444:513-522.
56. Hughes AK, Stricklett PK, Padilla E, Kohan DE. Effect of reactive oxygen species on endothelin-1 production by human mesangial cells. Kidney Int. 1996;49(1):181-189.
57. Vaage J, Valen G. Pathophysiology and mediators of ischemia-reperfusion injury with special reference to cardiac surgery. A review. Scand J Thorac Cardiovasc Surg Suppl. 1993;41:1-18.
58. Abu-Zidan FM, Walther S, Lennquist S. Role of platelet-activating factor on cardiovascular dysfunction in postischemic shock in pigs. Eur Surg Res. 1997;29(2):133-141.
59. Tamura Y, Imaoka S, Gemba M, Funae Y. Effects of ischemia-reperfusion on individual cytochrome P450 isoforms in the rat kidney. Life Sci. 1997;60(2):143-149.
60. Yue TL, Feuerstein GZ. Platelet-activating factor: A putative neuromodulator and mediator in the pathophysiology of brain injury. Crit Rev Neurobiol. 1994;8(1-2):11-24.
61. Donckier J, Hanet C, Stoleru L, Van-Mechelen H, Galanti L, Hayashida W, Keyeux A, Ketelslegers JM, Pouleur H. Effects of endothelin-1 at pathophysiologic concentrations on coronary perfusion and mechanical function of normal and postischemic myocardium. J Cardiovasc Pharmacol. 1994;23(2):212-219.
62. Cesari M, Pavan E, Sacchetto A, Rossi GP. ET-1: A scientist's curiosity, or a real player in ischemic heart disease? Am Heart J. 1996;132:1236-1243.
63. Clozel JP, Clozel M. Effects of endothelin on the coronary vascular bed in open-chest dogs. Circ Res. 1989;65:1193-1200.
64. Grover GJ, Sleph PG, Fox M, Trippodo NC. Role of endothelin-1 and big endothelin-1 in modulating coronary vascular tone, contractile function and severity of ischemia in rat hearts. J Pharmacol Exp Ther. 1992;263(3): 1074-1082.
65. Hirata K, Matsuda Y, Akita H, Yokoyama M, Fukuzaki H. Myocardial ischaemia induced by endothelin in the intact rabbit: Angiographic analysis. Cardiovasc Res 1990;24:879-883.
66. Cocks TM, Broughton A, Dib M, Sudhir K, Angus JA. ET is blood vessel selective: Studies on a variety of human and dog vessels in vitro and on regional blood flow in the conscious rabbit. Clin Exp Pharmacol Physiol. 1989;16:243-246.
67. Ezra D, Goldstein RE, Czaja JF, Feuerstein GZ. Lethal ischemia due to coronary endothelin in pigs. Am J Physiol. 1989;257:H339-H343.
68. 125I]endothelin-1 in humans, pigs, and rats: Functional relevance in humans. J Cardiovasc Pharmacol. 1989;13(S5):S166-S170.
69. Chester AH, Dashwood MR, Clarke JG, Larkin SW, Davies GJ, Tadjkarimi S, et al. Influence of ET on human coronary arteries and localization of its binding sites. Am J Cardiol. 1989;63:1395-1398.
70. Larkin SW, Clarke JG, Keogh BE, Araujo L, Rhodes C, Davies GJ, et al. Intracoronary ET induces myocardial ischemia by small vessel constriction in the dog. Am J Cardiol. 1989;64:956-958.
71. Vemulapalli S, Rivelli M, Chiu PJS, Del Prado M, He JA. Phosphoramidon abolishes the increases in endothelin-1 release induced by ischemia-hypoxia in isolated perfused guinea pig lungs. J Pharmacol Exp Ther. 1992;262(3):1062-1069.
72. Tsuji S, Sawamura A, Watanabe H, Takihara K, Park SE, Azuma J. Plasma endothelin levels during myocardial ischemia and reperfusion. Life Sci. 1991;48:1745-1749.
73. Tonnessen T, Naess PA, Kirkeboen KA, Offstad J, Ilebekk A, Christensen G. Release of endothelin from the porcine heart after short term coronary artery occlusion. Cardiovasc Res. 1993;27(8):1482-1485.
74. Watanabe T, Suzuki N, Shimamoto N, Fujino M, Imada A. ET in myocardial infarction. Nature. 1990;344:114.
75. Watanabe T, Suzuki N, Shimamoto N, Fujino M, Imada A. Contribution of endogenous endothelin to the extension of myocardial infarct size in rats. Circ Res. 1991;69:370-377.
76. Grover GJ, Dzwonczyk S, Parham CS. The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion. Cardiovasc Res. 1993;27(9):1613-1618.
77. Han H, Neubauer S, Braeker B, Ertl G. Endothelin-1 contributes to ischemia/reperfusion injury in isolated rat heart: Attenuation of ischemic injury by the endothelin-1 antagonists BQ123 and BQ610. J Mol Cell Cardiol. 1995;27(2):761-766.
78. Lee JY, Warner RB, Adler AL, Opgenorth TJ. Endothelin ETA receptor antagonist reduces myocardial infarction induced by coronary artery occlusion and reperfusion in the rat. Pharmacology. 1994;49(5):319-324.
79. Hagar JM, Geda M. Endogenous ET increases myocardial infarct size. Circ. 1995;92(S8):1455.
80. Li XS, Wang QD, Pernow J. Beneficial effects of the endothelin receptor antagonist bosentan on myocardial and endothelial injury following ischaemia/reperfusion in the rat. Eur J Pharmacol. 1995;283(1-3):161-168.
81. Wang QD, Li XS, Lundberg JM, Pernow J. Protective effects of non-peptide endothelin receptor antagonist bosentan on myocardial ischaemic and reperfusion injury in the pig. Cardiovasc Res. 1995;29(6):805-812.
82. Watanabe T, Awane Y, Ikeda S, Fujiwara S, Kubo K, Kikuchi T, Kusumoto K, Wakimasu M, Fujino M. Pharmacology of a non-selective ETA and ETB receptor antagonist, TAK-044, and the inhibition of myocardial infarct size in rats. Br J Pharmacol. 1995;114(5):949-954.
83. McMurdo L, Thiemermann C, Vane JR. The effects of the endothelin ET-A receptor antagonist, FR 139317, on infarct size in a rabbit model of acute myocardial ischaemia and reperfusion. Br J Pharmacol. 1994;112(1):75-80.
84. Mertz TE, McClanahan TB, Flynn MA, Juneau P, Reynolds EE, Hallak H, Bradford L, Gallagher KP. Endothelin-A receptor antagonism by PD 156707 does not reduce infarct size after coronary artery occlusion/reperfusion in pigs. J Pharmacol Exp Ther. 1996;278(1):42-49.
85. Richard V, Kaeffer N, Hogie M, Tron C, Blanc T, Thuillez C. Role of endogenous endothelin in myocardial and coronary endothelial injury after ischaemia and reperfusion in rats: Studies with bosentan, a mixed ET-A-ET-B antagonist. Br J Pharmacol. 1994;113(3):869-876.
86. Erikson JM, Velasco CE. Endothelin-1 and myocardial preconditioning. Am Heart J. 1996;132(1 part 1):84-90.
87. Velasco C, Yanagisawa M, Williamson J, Fernando Triana J. Cardioprotective action of ET-1 during ischemia. Circ. 1993;88(2):1544.
88. Velasco C, Yanagisawa M. ETs protect the ischemic myocardium. J Am Coll Cardiol. 1994;(S):30A.
89. Peng CF, Li YJ, Deng HW, Xiong Y. The protective effects of ischemic and calcitonin gene-related peptide-induced preconditioning on myocardial injury by endothelin-1 in the isolated perfused rat heart. Life Sci. 1996; 59(18):1507-1514.
90. Dawson DA, Masayasu H, Graham DI, Macrae IM. The neuroprotective efficacy of ebselen (a glutathione peroxidase mimic) on brain damage induced by transient focal cerebral ischaemia in the rat. Neurosci Lett. 1995;185(1):65-69.
91. Sagher O, Jin Y, Thai QA, Fergus A, Kassell NF, Lee KS. Cerebral microvascular responses to endothelins: The role of ET-A receptors. Brain Res. 1994;658(1-2):179-184.
92. Patel TR, Galbraith S, Graham DI, Hallak H, Doherty AM, McCulloch J. Endothelin receptor antagonist increases cerebral perfusion and reduces ischaemic damage in feline focal cerebral ischaemia. J Cerebr Blood Flow Met. 1996;16(5):950-958.
93. Touzani O, Galbraith S, Siegl P, McCulloch J. Endothelin-B receptors in cerebral resistance arterioles and their functional significance after focal cerebral ischemia in cats. J Cerebr Blood Flow Met. 1997;17:1157-1165.
94. Nikolov R, Rami A, Krieglstein J. Endothelin-1 exacerbates focal cerebral ischemia without exerting neurotoxic action in vitro. Eur J Pharmacol Environ Toxicol Pharmacol. 1993;2(2):205-208.
95. Fuxe K, Kurosawa N, Cintra A, Hallstrom A, Goiny M, Rosen L, Agnati LF, Ungerstedt U. Involvement of local ischemia in endothelin-1 induced lesions of the neostriatum of the anaesthetized rat. Exp Brain Res. 1992;88(1):131-139.
96. Robinson MJ, Macrae IM, Todd M, Reid JL, McCulloch J. Reduction of local cerebral blood flow to pathological levels by endothelin-1 applied to the middle cerebral artery in the rat. Neurosci Lett. 1990;118(20):269-272.
97. Macrae IM, Robinson MJ, Graham DI, Reid JL, McCulloch J. Endothelin-1-induced reductions in cerebral blood flow: Dose dependency, time course, and neuropathological consequences. J Cereb Blood Flow Met. 1993;13(2):276-284.
98. Sharkey J, Ritchie IM, Kelly PAT. Perivascular microapplication of endothelin-1: A new model of factor cerebral ischaemia in the rat. J Cereb Blood Flow Met. 1993;13(5):865-871.
99. Sharkey J, Butcher SP. Characterisation of an experimental model of stroke produced by intracerebral microinjection of endothelin-1 adjacent to the rat middle cerebral artery. J Neurosci Methods. 1995;60(1-2):125-131.
100. Gartshore G, Dawson D, Patterson J, Macrae IM. Consequences of transient focal cerebral ischaemia for second messenger and neurotransmitter binding in the rat: Quantitative autoradiographic analysis of forskolin, dopamine D-1 receptor binding and cerebral blood flow changes. Eur J Neurosci. 1996;8(3):486-493.
101. Gartshore G, Dawson D, Patterson J, Macrae IM. Topographic profile of reperfusion into MCA territory following endothelin-1-induced transient focal cerebral ischaemia. Neurosci Lett. 1996;202(3):209-213.
102. Sharkey J, Butcher SP, Kelly JS. Endothelin-1 induced middle cerebral artery occlusion: Pathological consequences and neuroprotective effects of MK801. J Autonom Nerv Syst. 1994;49:S177-S185.
103. Dawson DA, Graham DI, McCulloch J, Macrae IM. Anti-ischaemic efficacy of a nitric oxide synthase inhibitor and N-methyl-D-aspartate receptor antagonists in models of transient and permanent focal cerebral ischaemia. Br J Pharmacol. 1994;113(1):247-253.
104. Barone FC, Globus MYT, Price WJ, White RF, Storer BL, Feuerstein GZ, Busto R, Ohlstein EH. Endothelin levels increase in rat focal and global ischemia. J Cereb Blood Flow Met. 1994;14(2)337-342.
105. Giuffrida R, Malatino LS. Endothelin and transient cerebral ischemia: An immunohistochemical study in the Mongolian gerbil. Brain Dysfunction. 1992;5(3-4):192-199.
106. Gartshore G, Patterson J, Macrae IM. Influence of ischemia and reperfusion on the course of brain tissue swelling and blood-brain barrier permeability in a rodent model of transient focal cerebral ischemia. Exp Neurol. 1997;147(2):353-360.
107. Feuerstein G, Gu JL, Ohlstein EH, Barone FC, Yue TL. Peptidic endothelin-1 receptor antagonist, BQ-123, and neuroprotection. Peptides. 1994;15(3):467-469.
108. Spatz M, Yasuma Y, Strasser A, McCarron RM. Cerebral postischemic hypoperfusion is mediated by ET-A receptors. Brain Res. 1996;726(1-2):242-246.
109. Barone FC, White RF, Elliott JD, Feuerstein GZ, Ohlstein EH. The endothelin receptor antagonist SB 217242 reduces cerebral focal ischemic brain injury. J Cardiovasc Pharmacol. 1995;26(S3):S404-S407.
110. Barone FC, Willette RN, Yue TL, Feurestein G. Therapeutic effects of endothelin receptor antagonists in stroke. Neurol Res. 1995;17(4):259-264.
111. Tatlisumak T, Carano RAD, Takano K, Opgenorth TJ, Sotak CH, Fisher M. A novel endothelin antagonist, A-127722, attenuates ischemic lesion size in rats with temporary middle cerebral artery occlusion: A diffusion and perfusion MRI study. Stroke. 1998;29(4):850-857.
112. McAuley MA, Breu V, Graham DI, McCulloch J. The effects of bosentan on cerebral blood flow and histopathology following middle cerebral artery occlusion in the rat. Eur J Pharmacol. 1996;307(2):171-181.
113. Patel TR, McCulloch J. Failure of an endothelin antagonist to modify hypoperfusion after transient global ischaemia in the rat. J Cerebr Blood Flow Met. 1996; 16:490-499.
114. Patel TR, Galbraith SL, McAuley MA, Doherty AM, Graham DI, McCulloch J. Therapeutic potential of endothelin receptor antagonists in experimental stroke. J Cardiovasc Pharmacol. 1995;26(S3):S412-S415.
115. Patel TR, Galbraith S, McAuley MA, McCulloch J. Endothelin-mediated vascular tone following focal cerebral ischaemia in the cat. J Cerebr Blood Flow Met. 1996; 16(4):679-687.
116. Findlay JM, Macdonald RL, Weir BKA. Current concepts of pathophysiology and management of cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Cerebrovasc Brain Metab. 1991;3(4):336-361.
117. Kwan AL, Bavbek M, Jeng AY, Maniara W, Toyoda T, Lappe RW, Kassell NF, Lee KS. Prevention and reversal of cerebral vasospasm by an endothelin-converting enzyme inhibitor, CGS 26303, in an experimental model of subarachnoid hemorrhage. J Neurosurg. 1997;87(2):281-286.
118. Roux S, Breu V, Giller T, Neidhart W, Ramuz H, Coassolo P, Clozel JP, Clozel M. Ro 61-1790, a new hydroso-break luble endothelin antagonist: General pharmacology and effects on experimental cerebral vasospasm. J Pharmacol Exp Ther. 1997;283(3):1110-1118.
119. Takabatake T, Ise T, Ohta K, Kobayashi KI. Endothelin effects on renal function and tubuloglomerular feedback. Kidney Int. 1991;39:S122-5124.
120. Shibouta Y, Suzuki N, Shino A, Matsumoto H, Teashita ZI, Kondo K, et al. Pathophysiological role of endothelin in acute renal failure. Life Sci. 1990;46:1611-1618.
121. Sandok EK, Lerman A, Stingo AJ, Perrella MA, Gloviczki P, Burnett JC Jr. Endothelin, a model of acute ischemic renal dysfunction: Modulating action of atrial natriuretic factor. J Am Soc Nephrol. 1992;3(2):196-202.
122. Kon V, Yoshioka T, Fogo A, Ichikawa I. Glomerular action of endothelin in vivo. J Clin Invest. 1989;83:1762-1767.
123. Vemulapalli S, Chiu PJS, Chintala M, Bernardino V. Attenuation of ischemic acute renal failure by phosphoramidon in rats. Pharmacology. 1993;47(3):188-193.
124. Halim A, Kanayama N, Maehara K, Takahashi M, Terao T. HELPP syndrome-like biochemical parameters obtained with endothelin-1 injections in rabbits. Gynecol Obstet Invest. 1993;35(4):193-198.
125. Goto M, Takei Y, Kawano S, Nagano K, Tsuji S, Masuda E, Nishimura Y, Okumura S, Kashiwagi T, et al. Endothelin-1 is involved in the pathogenesis of ischemia/reperfusion liver injury by hepatic microcirculatory disturbances. Hepatology. 1994;19(3):675-681.
126. Spiegel HU, Uhlmann D, Scommotau S, Giersch B, Sulkowski U. Effect of the endothelin receptor antagonist bosentan on postischemic oxygen supply of the liver. J Invest Surg. 1996;9(6):439-445.
127. Koeppel TA, Kraus T, Thies JC, Gebhardl MM, Otto G, Post S. Effects of mixed ET-A and ET-B-receptor antagonist (Ro-47-0203) on hepatic microcirculation after warm ischemia. Digest Dis Sci. 1997;42(6):1316-1321.
128. Kitayama Y, Yamanaka N, Kawamura E, Kuroda N, Okamoto E. Hepatoprotective effect of the endothelin receptor antagonist TAK-044 against ischemia-reperfusion injury in the canine liver. Hepatology. 1997;25(4):938-942.
129. Jin MB, Zhu Y, Zhang S, Ishizaki N, Tanaka H, Subbotin VM, Lee RG, Starzl TE, Todo S. Attenuation of ischemic liver injury by a non-selective endothelin receptor antagonist. Transplant Proc. 1997;29(1-2):1335.
130. Peralta C, Closa D, Hotter G, Gelpi E, Prats N, Rosello-Catafau J. Liver ischemic preconditioning is mediated by the inhibitory action of nitric oxide on endothelin. Biochem Biophys Res Commun. 1996;229(1):264-270.
131. Pannen BH, Al-Adili F, Bauer M, Clemens MG, Geiger KK. Role of endothelins and nitric oxide in hepatic reperfusion injury in the rat. Hepatology. 1998;27(3):755-764.
132. Hvaal K, Oie E, Attramadal H, Halvorsen V, Svindland A, Nordsletten L, Skjeldal S. Endothelin-1 is upregulated during skeletal muscle ischemia and reperfusion. J Orthopaed Res. 1998;16(1):128-135.
133. Chang H, Wu GJ, Wang SM, Hung CR. The role of endothelin-1 during ischemia-reperfusion injury. Formosan Med Assoc. 1992;91(12):1182-1188.
134. Miura S, Kurose I, Fukumura D, Suematsu M, Sekizuka E, Tashiro H, Serizawa H, Asako H, Tsuchiya M. Ischemic bowel necrosis induced by endothelin-1: An experimental model in rats. Digestion. 1992;48(3):163-172.
135. Yegen C, Aktan AO, Buyukgebiz O, Haklar G, Yalcin AS, Yalin R, Ercan S. Effect of verapamil and iloprost (ZK 36374) on endothelin release after mesenteric ischemia-reperfusion injury. Eur Surg Res. 1994;26(2):69-75.
136. Michida T, Kawano S, Masuda E, Kobayashi I, Nishimura Y, Tsujii M, Hayashi N, Takei Y, Tsuji S, Nagano K, Fusamoto H, Kamada T. Role of endothelin 1 in hemorrhagic shock-induced gastric mucosal injury in rats. Gastroenterol Jpn. 1994;6(4):988-993.
137. Ma JC, Liu YY, Liu HB, Wei GZ, Sheng SL, Yue XH, Tian N. Effect of endothelin 1 on cerebral microcirculation and antagonistic action of drugs in rats with hemorrhagic shock. Zhongguo Yaolixue Yu Dulixue Zazhi. 1994;8(3):175-178.
138. Watschinger B, Vychytil A, Schuller M, Hartter E, Traindl O, Pohanka E, et al. The pathophysiologic role of ET in acute vascular rejection after renal transplantation. Transplantation. 1991;52:743-746.
139. Yamakado M, Hirata Y, Matsuoka H, Sugimoto T. Pathophysiological role of ET in renal transplantation. J Cardiovasc Pharmacol. 1991;17:5477-5479.
140. Aharinejad S, Nourani F, Egerbacher M, Larson EK, Miksovsky A, Bock P, Firbas W, McCuskey RS, Marks SC Jr. Sphincters of canine hepatic sublobular veins respond to endothelin-1 and -3. Anat Embryol. 1997; 196(4):299-309.
141. Yamanaka N, Takaya Y, Oriyama T, Furukawa K, Tanaka T, Tanaka W, Ichikawa N, Yasui C, Ando T, Yamanaka J, Kuroda N, Ko M, Takada M, Imakita M, Kitayama Y, Okamoto E, Sasaki S, Nakagaki I, Hori S, Ito T. Hepatoprotective effect of a nonselective endothelin receptor antagonist (TAK-044) in the transplanted liver. J Surg Res. 1997;70(2):156-160.
142. Zoja C, Furci L, Ghilardi F, Zilio P, Benigni A, Remuzzi G. Cyclosporin-induced endothelial cell injury. Lab Invest. 1986;55:455-462.
143. Epstein A, Beall A, Wynn J, Mulloy L, Brophy CM. Cyclosporine, but not FK506, selectively induces renal and coronary artery smooth muscle contraction. Surgery. 1998;123(4):456-460.
144. Kon V, Sugiura M, Inagami T, Harvie BR, Ichikawa I, Hoover RL. Role of endothelin in cyclosporine-induced glomerular dysfunction. Kidney Int. 1990;37(6):1487-1491.
145. Grieff M, Shoheib SA, Loertscher R, Stewart DJ. Cyclosporine induces elevation in circulating ET-1 following transplantation. J Am Soc Nephrol. 1990;1:758A.
146. Bunchman TE, Brookshire CA. Cyclosporine-induced synthesis of endothelin by cultured human endothelial cells. J Clin Invest. 1991;88:310-314.
147. Ohta K, Hirata Y, Imai T, Kanno K, Emori T, Shichiri M, et al. Cytokine-induced release of ET-1 from porcine renal epithelial cell line. Biochem Biophys Res Commun. 1990;169:578-584.
148. Nambi P, Pullen M, Contino LC, Brooks DP. Upregulation of renal ET receptors in rats with CsA-induced nephrotoxidty. Eur J Pharmacol. 1990;187:113-116.
149. Brooks DP, Ohlstein EH, Contino LC, Storer B, Pullen M, Caltabiano M, Nambi P. Effect of nifedipine on CsA-induced nephrotoxicity, urinary ET excretion, and renal ET receptor number. Eur J Pharmacol. 1991;194:115-117.
150. Nayler W. Endothelin: Isoforms, binding sites and possible implications in pathology. Trends Pharmacol Sci. 1990;11:96-99.
151. Perico N, Dadan J, Remuzzi G. ET mediates the renal vasoconstriction induced by cyclosporine in the rat. J Am Soc Nephrol. 1990;1:76-83.